Biogen has agreed to acquire RayThera in a deal valued at up to $1 billion, gaining access to a pipeline of anti-inflammatory drug candidates led by a program that is expected to enter clinical testing in the near future.
RayThera emerged from stealth last year with a $110 million series A financing round intended to advance a portfolio of small-molecule therapies targeting immunological diseases through preclinical development. Public information about the company’s pipeline remains limited, with only three assets disclosed. According to the company’s pipeline description, the candidates target undisclosed biological pathways and are being developed for undisclosed inflammatory conditions, with programs currently in lead optimization and preclinical stages.
Biogen has not provided a detailed breakdown of the acquisition terms. The company stated only that the transaction includes an upfront payment but that the majority of the potential $1 billion value is tied to future clinical and regulatory milestone achievements. Biogen also indicated that RayThera’s lead candidate is expected to begin clinical development early in the third quarter.
Analysts at BMO Capital Markets identified RayThera patent filings related to tumor necrosis factor (TNF) modulators, CCR4 inhibitors and STAT6 modulators. According to the analysts, these patents may offer clues regarding the biological targets the company is pursuing. Several pharmaceutical companies have explored these pathways, including Sanofi, which has invested in STAT6-targeted therapies. Meanwhile, Rapt Therapeutics discontinued development of a CCR4 inhibitor in 2024 after the FDA placed a midstage clinical study on hold.
The acquisition is expected to strengthen Biogen’s immunology portfolio, which analysts described as already substantial. The growing pipeline aligns with the company’s open innovation strategy, a framework that Head of Immunology Research Nick Wilson recently described as central to Biogen’s efforts to build its next generation of therapies through external partnerships, licensing agreements and acquisitions.
The transaction also marks another successful exit for RayThera co-founders Qing Dong and Gene Hung, who launched the company in 2023 and served as chief executive officer and chief scientific officer, respectively. The pair previously co-founded XinThera in 2021 and sold the company to Gilead for $200 million upfront in 2023.
For Dong, the deal represents a third successful company exit. Prior to XinThera, he founded FronThera in 2015 and helped guide the company to its acquisition by Alumis in 2021.
RayThera’s leadership team also included several former XinThera executives. Kyle Fraher, Mary Giesonand Jing Liu, all of whom previously worked at XinThera, held vice president-level or more senior positions at RayThera, helping assemble a team that rapidly advanced the company’s programs toward clinical readiness.
The RayThera acquisition follows another major transaction by Biogen: its $5.6 billion purchase of Apellis Pharmaceuticals in March. At the time, CEO Chris Viehbacher indicated that the acquisition represented the strongest strategic fit for Biogen and aligned closely with the direction of the company’s evolving pipeline.
Through the Apellis deal, Biogen added two FDA-approved therapies to its portfolio. These include Syfovre, which is approved for geographic atrophy secondary to age-related macular degeneration, and Empaveli, approved for the treatment of C3 glomerulopathy.
Biogen has announced a landmark $1 billion agreement to acquire RayThera, significantly strengthening its presence in immunology research. The acquisition brings a portfolio of promising preclinical assets designed to address immune-mediated diseases, reinforcing Biogen’s long-term strategy of expanding beyond its established neuroscience business.
Biogen Expands Its Immunology Pipeline
The acquisition provides Biogen with access to innovative preclinical therapies that may offer new treatment options for autoimmune and inflammatory disorders. By integrating RayThera’s research capabilities, Biogen aims to accelerate the development of next-generation immunology medicines.
For Biogen, this transaction represents more than a pipeline expansion. It reflects the company’s commitment to investing in early-stage scientific innovation with the potential to generate long-term value. RayThera’s technology platform complements Biogen’s growing focus on diseases driven by immune system dysfunction.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
